21 November 2023 ORYZON announces a New Financing through a Convertible Bond Program for a total amount of up to €45 million
7 November 2023 ORYZON announces Last Patient Last Visit in its Phase IIb PORTICO study for Borderline Personality Disorder (BPD)
27 October 2023 ORYZON reports financial results and corporate updates for quarter ended September 30, 2023
10 October 2023 ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder